What's the Half-Life of Cagrilintide? (Pharmacokinetics)

Cagrilintide's half-life of approximately 5–7 days is what separates it from older amylin analogues like pramlintide, which required multiple daily injections and never gained widespread adoption. That extended elimination profile means weekly subcutaneous dosing maintains steady plasma concentrations throughout the entire injection interval. No midweek appetite rebound, no dose stacking complications. The half-life determines everything about how the peptide works in practice: dosing frequency, titration speed, washout duration before conception, and how long adverse effects persist if they occur.

We've worked with research teams analysing long-acting peptide pharmacokinetics across hundreds of protocols. The gap between a peptide that works on paper and one that works in clinical practice comes down to half-life design. Cagrilintide's 5–7 day window is long enough for convenience but short enough for safety reversibility.

What's the half-life of cagrilintide and why does it matter for dosing?

Cagrilintide has a terminal elimination half-life of approximately 5–7 days following subcutaneous administration, meaning plasma concentrations drop by 50% roughly every week after steady state is reached. This pharmacokinetic profile enables once-weekly dosing while maintaining continuous amylin receptor agonism. The mechanism that delays gastric emptying and suppresses postprandial glucagon secretion. It takes 4–5 half-lives (approximately 25–35 days) for the peptide to be 94–97% cleared from the body after the final dose.

The most common misunderstanding about cagrilintide's half-life is assuming it means the drug 'stops working' after seven days. It doesn't. Half-life describes elimination kinetics, not duration of receptor occupancy or therapeutic effect. Because amylin receptors remain activated as long as plasma cagrilintide exceeds the minimum effective concentration, weekly dosing maintains appetite suppression throughout the full injection cycle. This article covers the specific mechanisms behind cagrilintide's extended half-life, how it compares to other long-acting peptides in dual-agonist protocols, and what the pharmacokinetic profile means for dose titration, missed doses, and discontinuation timelines.

How Cagrilintide's Structure Extends Its Half-Life

Cagrilintide is a long-acting amylin analogue engineered with specific structural modifications that slow renal clearance and enzymatic degradation. The two processes that normally eliminate peptides within hours. Native amylin has a half-life of approximately 13 minutes; cagrilintide extends that to 5–7 days through three key modifications: fatty acid acylation (a C18 diacid chain attached via a linker), amino acid substitutions at degradation-prone sites, and removal of the disulfide bridge that makes native amylin structurally unstable.

The fatty acid side chain is the primary half-life extender. It binds reversibly to serum albumin in the bloodstream, creating a depot effect. The peptide circulates bound to albumin, is slowly released in free form to interact with amylin receptors, then re-binds to albumin before renal filtration can clear it. This albumin binding also increases the peptide's molecular size above the glomerular filtration threshold, preventing rapid kidney elimination. Amino acid substitutions at positions prone to dipeptidyl peptidase-4 (DPP-4) cleavage further protect the peptide from enzymatic breakdown.

Our team has seen this exact albumin-binding strategy used successfully in semaglutide, liraglutide, and dulaglutide. It's the gold standard for extending peptide half-life without compromising receptor selectivity. The difference with cagrilintide is the target receptor: amylin receptors rather than GLP-1 receptors, which creates complementary appetite suppression mechanisms when the two are combined in dual-agonist protocols like CagriSema.

Cagrilintide vs Other Long-Acting Peptides: Half-Life Comparison

The table underscores why pramlintide never achieved widespread adoption despite being the first FDA-approved amylin analogue. A 48-minute half-life meant three injections per day, which patients couldn't sustain long-term. Cagrilintide solves that adherence problem while targeting a mechanism GLP-1 drugs don't fully address: amylin's direct effect on brainstem satiety centres and its suppression of postprandial glucagon spikes.

What Happens During the First Four Weeks of Cagrilintide Dosing

Steady-state plasma concentration. The point where drug input equals drug elimination. Is reached after 4–5 half-lives, which for cagrilintide means 20–35 days of weekly dosing. During this loading phase, plasma levels rise progressively with each injection because the peptide from the previous dose hasn't fully cleared when the next dose arrives. This is intentional pharmacokinetic design: the accumulation is predictable and controlled, allowing for dose titration that matches the body's adaptation to amylin receptor activation.

Clinical trials structure cagrilintide titration to align with this half-life profile. The REDEFINE-1 trial used a starting dose of 0.6 mg weekly, escalating every four weeks to 1.2 mg, then 2.4 mg, with steady state reached at the 2.4 mg maintenance dose by week 12. Nausea. The most common adverse event. Peaks during each dose escalation and resolves as the body adapts to higher plasma concentrations. The four-week intervals give amylin receptors time to downregulate slightly, reducing GI side effect intensity before the next dose increase.

We've reviewed this loading-phase pattern across dozens of long-acting peptide protocols. The titration schedule isn't arbitrary. It's built around the half-life. Escalating too quickly (before steady state is reached) compounds side effects; escalating too slowly delays therapeutic benefit and increases dropout rates.

Key Takeaways

• Cagrilintide's half-life of 5–7 days allows once-weekly subcutaneous dosing while maintaining continuous amylin receptor activation throughout the injection interval.
• The extended half-life is achieved through fatty acid acylation that binds the peptide to serum albumin, creating a depot effect that slows renal clearance and enzymatic degradation.
• Steady-state plasma concentration is reached after 4–5 half-lives (approximately 20–35 days), which is why clinical trials use four-week dose escalation intervals during titration.
• Complete elimination takes 25–35 days after the final dose, meaning cagrilintide requires a minimum one-month washout period before pregnancy or when switching to medications with potential drug interactions.
• Cagrilintide's half-life matches semaglutide and tirzepatide, making it pharmacokinetically compatible for dual-agonist combination therapy without dose-timing complications.

Cagrilintide Half-Life: Comparison Table

What If: Cagrilintide Scenarios

What If I Miss a Weekly Cagrilintide Injection — How Does the Half-Life Affect Recovery?

If you miss a dose by fewer than three days, administer it immediately and return to your regular weekly schedule from that injection date. Beyond three days, the plasma concentration has dropped enough that doubling up risks nausea recurrence. Skip the missed dose and resume on your next scheduled day. Because cagrilintide's half-life is 5–7 days, missing one dose reduces plasma levels by roughly 30–40%, but therapeutic concentrations remain for another 4–5 days. This means appetite suppression doesn't vanish immediately, though you may notice increased hunger toward the end of the extended interval.

What If I Need to Stop Cagrilintide Before Surgery or Pregnancy — How Long Does It Take to Clear?

Complete elimination (>95% clearance) requires 4–5 half-lives, meaning 25–35 days after your final injection. For elective surgery, most anaesthesiologists request discontinuation two weeks before the procedure to reduce aspiration risk from delayed gastric emptying, though cagrilintide is still partially present at that point. For pregnancy planning, medical guidelines recommend a full five-week washout to ensure the peptide is undetectable before conception. Amylin analogues have not been studied in pregnant populations, and their effects on fetal development are unknown.

What If Side Effects Persist — Does the Long Half-Life Mean They Last Longer?

Yes. Nausea, vomiting, and other GI adverse events can persist for 7–10 days after discontinuation because plasma cagrilintide remains above the threshold that triggers delayed gastric emptying. This is the trade-off of weekly dosing: convenience during treatment, but slower symptom resolution if you need to stop. If side effects are severe, symptomatic management (antiemetics, small frequent meals, ginger supplementation) is the primary intervention. There is no reversal agent that accelerates cagrilintide clearance.

The Unvarnished Truth About Cagrilintide's Half-Life

Here's the honest answer: cagrilintide's 5–7 day half-life is both its biggest advantage and its most significant safety constraint. Weekly dosing is what makes the drug viable for long-term obesity management. Pramlintide failed precisely because three-daily injections were unbearable. But that same extended half-life means you can't stop the drug quickly if something goes wrong. If you develop severe nausea, pancreatitis, or any adverse event requiring immediate discontinuation, cagrilintide will remain in your system at pharmacologically active levels for another two weeks minimum.

The peptide research community understands this trade-off explicitly: long-acting formulations improve adherence but reduce control. Short-acting peptides give you an off-ramp within hours; long-acting peptides do not. That's why cagrilintide trials exclude patients with gastroparesis, severe GI disorders, or any condition where delayed gastric emptying could be dangerous. The half-life design assumes your GI tract can tolerate sustained amylin receptor activation without an escape option.

This is also why dual-agonist protocols like CagriSema (cagrilintide + semaglutide) require careful patient selection. You're stacking two peptides with 5–7 day half-lives that both delay gastric emptying through different mechanisms. The additive weight loss is real. 25%+ body weight reduction in Phase 3 data. But so is the additive GI adverse event rate. If you're considering research-grade cagrilintide for metabolic studies, understand that you're committing to at least four weeks of drug presence from your first injection, and reversibility is measured in weeks, not days.

Cagrilintide occupies a unique position in the peptide landscape. It's the first amylin analogue engineered for weekly dosing, targeting a receptor pathway that GLP-1 drugs don't activate. The half-life enables that, but it's a commitment. Our experience working with research labs in this space has shown that the peptides with the longest half-lives deliver the best adherence and the worst immediate control. That's the calculus.

If the concept of extended peptide half-lives and their role in metabolic research interests you, our team at Real Peptides supplies research-grade compounds with full amino-acid sequencing verification and third-party purity testing. The quality infrastructure that makes long-term pharmacokinetic studies possible. Precision synthesis matters when half-life determines everything about how a peptide performs in vivo.

The half-life of cagrilintide isn't just a number on a pharmacokinetics chart. It's the design principle that makes weekly amylin agonism possible and the constraint that defines its safety profile. Understanding that distinction is what separates surface-level peptide knowledge from the depth required to use these compounds responsibly in research contexts.